• Akira Sawaki, Kazuhiko Ohashi, Kenji Yamao, InadaKen-IchiK, Yasuhiro Shimizu, Akira Matsuura, Tuneya Nakamura, Takashi Suzuki, Kazuo Hara, Kenji Okubo, and Ryuzo Ohno.
• Department of Gastroenterology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-0021, Japan.
• J. Gastroenterol. 2003 Jan 1; 38 (7): 690-4.

AbstractGastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors. The molecular etiology is the result of mutations in the c-Kit gene. The mutant c-Kit proteins, which are activated without a stem cell factor, contribute to the tumor development. STI571 selectively inhibits c-Kit, BCR-ABL, and PDGFR tyrosine kinases. Based on this potential to inhibit critical c-Kit function in GISTs, case studies have reported effective outcomes following treatment with STI571. This case report describes a highly effective use of STI571 in a 54-year-old woman with multiple liver metastases from a GIST originating in the duodenum.

19 keywords...

hide…